Evidence map›Paper›PMID 37659014›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2023

Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis.

Shan Yang, Renzi Zhang, Wenzhen Deng, Shichuan Chang, Yang Li, Sheng Li

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Shan YangDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Renzi ZhangDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wenzhen DengDepartment of Endocrinology, Qianjiang Central Hospital of Chongqing, Chongqing, 409000, China.
Shichuan ChangOncology Department, Chongqing University Three Gorges Hospital, Chongqing, 404000, China.
Yang LiDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 305990@hospital.cqmu.edu.cn.
Sheng LiDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. lisheng@stu.cqmu.edu.cn.
Chongqing Medical University · CNChongqing University · CNQianjiang Central Hospital · CNSecond Affiliated Hospital of Chongqing Medical University · CN

Funding

Chinese Postdoctoral Science Foundation 2021M700633Joint project of Chongqing Health Commission and Science and Technology Bureau 2020FYYX029Postdoctoral Special Foundation of Chongqing 2022CQBSHTB3045the China Endocrinology and Metabolism Young Scientific Talent Research Project Grant no. 2021-N-03the National Natural Science Foundation of China 82100824the Natural Science Foundation Project of CQ cstc2021jcyj-msxmX0074
6 · The paper itself

Abstract

objectivePrevious studies reported that pirfenidone (PFD) is associated with liver disease. However, the effects of pirfenidone on energy metabolism and hepatic lipid accumulation are still poorly understood.

methodsIn this study, C57BL/6J mice were randomly divided into two groups, and fed a normal chow diet (NCD) or a high-fat diet (HFD) for 16 weeks. At the end of the eighth week, half of the mice fed on both diets were treated with PFD. Biochemical and lipid metabolism-related indices were analyzed. Furthermore, Hepa 1-6 cells and mouse primary hepatocytes (MPHs) were incubated with PFD with or without free fatty acid (FFA) treatment. Then, stattic (a p-STAT3 inhibitor) or Ad-shSTAT3 was used to further elucidate the effects of Signal Transducer and Activator of Transcription 3 (STAT3) signaling on PFD regulation of hepatic steatosis.

resultsPFD ameliorated obesity and hepatic lipid deposition in HFD mice by decreasing stearoyl-CoA desaturase 1 (SCD1) expression and upregulating p-STAT3 in the liver. In Hepa 1-6 cells and MPHs, PFD also down-regulated the expression of SCD1. STAT3 inhibition treatment eliminated the benefits of PFD on both SCD1 and hepatic steatosis.

conclusionIn summary, our data reveal that PFD may play an important role in mitigating hepatic steatosis in a STAT3-SCD1-dependent manner.

Indexed as

Fatty LiverSTAT3 Transcription FactorAnimalsDiet, High-FatLipidsLiverMiceMice, Inbred C57BLPyridonesLipidspirfenidonePyridonesSTAT3 Transcription FactorHepatic steatosisMetabolism-associated fatty liver diseasePirfenidoneSignal transducer and activator of transcription 3Stearoyl-CoA desaturase 1

Identifiers

PMID37659014
OpenAlexW4386390956

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.